Close Menu

Are cancer biomarkers all they're cracked up to be? Not always, writes Monica Desai in the Guardian's science blog. Of the thousands of biomarkers researchers are aware of, only a small percentage of them is being used in the clinic to find treatments for disease. There have been successes like HER-2 in breast cancer which led to the formulation of Herceptin, Desai says, but not every biomarker turns out to be as useful.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.